iRhythm Holdings, Inc. (IRTC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal positive financial performance with strong revenue growth, improved margins, and positive free cash flow. The company's strategic initiatives, including partnerships and technological advancements, are well-received, despite some uncertainties in guidance. The Q&A reflects optimism about future growth and the impact of CMS proposals, AI, and wearables. The stock market cap indicates a moderate reaction, suggesting a positive stock price movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue (Q4 2025) $208.9 million, representing 27.1% year-over-year growth. Growth driven by sustained volume demand across customer base and contributions from newer growth channels.
Revenue (Full Year 2025) $747.1 million, representing 26.2% growth compared to 2024. Growth primarily driven by sustained volume demand and favorable pricing improvements.
Gross Margin (Q4 2025) 70.9%, an increase of 90 basis points year-over-year. Improvement driven by operational efficiencies, manufacturing automation, workflow optimization, and scale benefits.
Gross Margin (Full Year 2025) 70.6%, an improvement of 170 basis points year-over-year. Improvement due to operational efficiencies and scale benefits, partially offset by product mix.
Operating Expenses (Q4 2025) $145.8 million, compared to $119.2 million in the prior year period. Increase due to purposeful investments to fuel growth.
Operating Expenses (Full Year 2025) $584.7 million, an increase of 11.8%. Investments made to support near, mid, and long-term growth.
Net Income (Q4 2025) $5.6 million or $0.17 per diluted share. First positive quarterly net income in iRhythm's history.
Net Loss (Full Year 2025) $44.6 million or a loss of $1.39 per diluted share.
Adjusted EBITDA (Q4 2025) $34.3 million or 16.4% of revenue, representing a 470 basis point improvement year-over-year.
Adjusted EBITDA (Full Year 2025) $68.9 million or 9.2% of revenue, representing an improvement of more than 1,000 basis points compared to 2024.
Free Cash Flow (Q4 2025) $14.5 million. First positive free cash flow quarter in iRhythm's history.
Free Cash Flow (Full Year 2025) $34.5 million. First year of positive free cash flow in iRhythm's history.
Cash, Cash Equivalents, and Marketable Securities (End of 2025) $583.8 million, providing substantial flexibility for future growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-gen MCT device: Currently under FDA review, featuring a 21-day wear time, improved form factor, and enhanced algorithms. Expected release in the first half of 2027.
Zio AT offering: Continues to perform well with unit growth running more than twice the company average for the year. Supported by new account wins and increased prescribing.
Predictive AI capabilities: Advanced significantly in 2025, combining internal and external data to identify patients at risk of arrhythmias with over 85% accuracy in early pilots.
International markets: Commercial presence in the U.K., select EU markets, and Japan. Less than 1% market share in regions conducting over 3 million tests annually. Largest quarter of volume in the U.K. and participation in NHS pilots.
Primary care expansion: More than 1/3 of volume originated in primary care settings. Serving approximately 40,000 primary care physicians, supported by EHR integrated workflows and innovative channel partnerships.
Revenue growth: Achieved 27.1% year-over-year growth in Q4 2025 and 26.2% growth for the full year 2025, driven by sustained volume demand.
Gross margin improvement: Full year gross margin improved by 170 basis points to 70.6%, driven by operational efficiencies and scale benefits.
Profitability milestone: First year of positive adjusted EBITDA and free cash flow in company history, with $34.5 million free cash flow for 2025.
Shift to proactive care: Moving from episodic detection to proactive, integrated, and predictive care. Focus on long-term continuous monitoring and addressing gaps in arrhythmia detection.
EHR integration strategy: More than half of volume flows through EHR integrated accounts, creating stickiness and long-term account durability.
Focus on value-based care: Aligning with value-based care and population health by expanding primary care footprint and enabling earlier detection.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The next-generation MCT device is currently under FDA review, and the company is in active dialogue with the agency to address their questions. This regulatory process could delay the product's release, impacting future revenue and market share expansion.
Market Share Disparity: iRhythm holds only 15% market share in the MCT market compared to 72% in long-term cardiac monitoring. This disparity highlights a challenge in gaining a stronger foothold in the MCT market, which could limit revenue growth.
International Market Penetration: Despite being commercial in the U.K., select EU markets, and Japan, iRhythm holds less than 1% market share in these regions. Scaling these markets requires disciplined execution, evidence generation, and reimbursement progression, which could pose challenges.
Healthcare Access Constraints: Nearly half of U.S. counties and close to 90% of rural counties lack cardiologists, creating access issues. While iRhythm is addressing this by shifting detection to primary care, the constrained healthcare system remains a challenge.
Audit Sensitivity and Compliance: The industry is facing heightened scrutiny around medical documentation practices, including chart scraping behaviors. iRhythm must maintain operational excellence and compliance to avoid potential regulatory or reputational risks.
Economic and Operational Scalability: While the company achieved profitability and free cash flow positivity, sustaining operational efficiencies and scaling profitably in a rapidly evolving healthcare environment remains a challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For the full year 2026, revenue is expected to be in the range of $870 million to $880 million, representing 16% to 18% year-over-year growth. First quarter 2026 revenue is anticipated to be in the range of $193 million to $195 million.
Gross Margin: Gross margin is expected to incrementally improve for the full year 2026 due to clinical operations and manufacturing efficiencies, leveraging fixed cost infrastructure, and introducing new AI and workflow tools.
Adjusted EBITDA Margin: Adjusted EBITDA margin is projected to expand to 11.5% to 12.5% of revenue in 2026, with the first quarter expected to be between 3% and 4% of revenue.
Free Cash Flow: Free cash flow is expected to grow versus 2025, with more heavily weighted contributions in the second half of the year due to normal operating seasonality.
Product Launch: The next-generation MCT device, featuring a 21-day wear time, improved form factor, and enhanced algorithms, is expected to be released in the first half of 2027, pending FDA review.
International Expansion: Focus remains on disciplined execution, evidence generation, and reimbursement progression in international markets, including the U.K., EU, and Japan, where iRhythm holds less than 1% market share.
AI and Predictive Capabilities: iRhythm is advancing predictive AI capabilities, combining ECG data with external datasets to identify patients at risk of arrhythmias before diagnosis. Early pilots show over 85% accuracy in pre-identifying clinically relevant arrhythmias.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What concerns have been raised about the elimination of chart-derived diagnosis from CMS and its impact on Zio use?
A:Quentin Blackford explained that Zio addresses concerns around chart-derived diagnosis by providing confirmatory diagnoses that integrate into patient records. He also mentioned that Zio reduces the cost of care, with data expected to be published later this year to support this claim.
Q:Did the company provide guidance for gross and operating margins for 2026?
A:Daniel Wilson stated that the company provided guidance for adjusted EBITDA margin of 11.5% to 12.5% for the full year and 3% to 4% for Q1 2026. Gross margin is expected to improve by 80 to 100 basis points relative to 2025.
Q:Could the CMS proposal on chart scraping be a tailwind for Zio Monitors and LTCM patches?
A:Quentin Blackford expressed optimism that the CMS proposal could be a tailwind as partners focus on confirmatory diagnoses. However, the company has not factored this into forward-looking expectations yet.
Q:What are the company’s thoughts on AI concerns in med tech and its impact on their business?
A:Quentin Blackford emphasized that iRhythm’s platform is differentiated by its clean ECG data, FDA-cleared algorithms, and deep EHR integrations. He expressed confidence in the company’s ability to stay ahead in AI due to its extensive data set and regulatory expertise.
Q:What is the status of the MCT product and its expected launch timeline?
A:Quentin Blackford confirmed that the MCT product is on track for a first-half 2027 launch. The product will feature a mobile gateway, extended duration to 21 days, enhanced algorithms, and improved patient experience. The company is working with the FDA to finalize the submission.
Q:What does the company mean by a 'disciplined approach to forecasting' in its 2026 guidance?
A:Daniel Wilson explained that the company aims to provide thoughtful guidance, leaving upside opportunities out of the initial forecast. Core U.S. monitor growth, Zio AT momentum, and innovative channel contributions are key components of the guidance.
Q:What is included in the 2026 guidance for innovative channel partnerships?
A:Daniel Wilson stated that the 2026 guidance includes a step-up from the Q4 2025 run rate, with new partners added in Q4 and Q1. The innovative channel remains a small but fast-growing part of the business.
Q:How does the company view the impact of wearable devices on its business?
A:Quentin Blackford noted that wearable devices serve as a lead generator for Zio prescriptions but are not a significant driver for innovative channel partnerships. These partnerships focus on targeted populations for confirmatory diagnoses.
Q:What are the company’s plans for updating its long-range plan (LRP) targets?
A:Quentin Blackford stated that the company will consider refreshing its LRP targets as it approaches the $1 billion revenue goal in 2027. He highlighted the company’s strong position and growth opportunities in core and innovative channels.
Q:What is the company’s approach to addressing cybersecurity concerns for the new MCT product?
A:Quentin Blackford explained that the company decided to move to a new mobile gateway to address cybersecurity concerns, rather than updating the old gateway. This decision aligns with long-term business health and regulatory requirements.
Q:What is the company’s outlook on repeat monitoring in innovative channel partnerships?
A:Quentin Blackford mentioned that discussions on repeat monitoring are ongoing, with some partners considering annual or triennial monitoring. He expects repeat testing to become a standard practice as programs mature.
Q:How did pricing trends impact the company’s 2025 performance and 2026 guidance?
A:Daniel Wilson noted that 2025 pricing came in better than expected due to favorable product mix and improved collections. For 2026, pricing is expected to remain flat, with Medicare rate increases for Zio Monitor offset by slight decreases for Zio AT.
Q:What is the company’s progress with Epic Aura integrations?
A:Quentin Blackford reported record Epic integrations in Q4 2025 and a strong pipeline for 2026. Integrated systems drive a 25% increase in prescribing volume within six months, though this is not fully factored into guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of innovative channel partners and their scaling timelines, citing variability and limited visibility. Additionally, they did not provide a clear timeline for refreshing long-range plan targets or specifics on repeat monitoring practices in innovative channels.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI scale
EHR
UK
Zio Monitor
arrhythmia program
audit
cardiology care
care environment
care utilization
cash flow
collection
cost care
county
delivery
demand
detection
discipline
driver
durability
flow cash
history
hour
improvement basis
income
market share
milestone
model
pilot
point improvement
power
prescribing
pricing
profile
provider payer
risk arrhythmia
scale benefit
seasonality
share term
shift
sleep
term monitoring
tool
value care
IRTC Transcript
i-80 Gold Corp. (IAU:CA) Q4 2025 Earnings Call Transcript
Unknown2-20
The earnings call reflects several challenges: increased operational expenses, permitting delays, and heavy reliance on financing, which strain cash flows. Despite achieving production guidance and increased gold sales, the net loss widened significantly. The Q&A session revealed unclear management responses and a lack of detailed cost information, further clouding the outlook. These factors, combined with economic uncertainties and operational risks, suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
iRhythm Holdings, Inc. (IRTC) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary and Q&A reveal positive financial performance with strong revenue growth, improved margins, and positive free cash flow. The company's strategic initiatives, including partnerships and technological advancements, are well-received, despite some uncertainties in guidance. The Q&A reflects optimism about future growth and the impact of CMS proposals, AI, and wearables. The stock market cap indicates a moderate reaction, suggesting a positive stock price movement of 2% to 8% over the next two weeks.
iRhythm Technologies, Inc. (IRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
iRhythm Technologies, Inc. (IRTC) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
IRTC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
